BTIG Affirms Regeneron (REGN) at 'Neutral' as ODYSSEY OUTCOMES Trial to Continue

November 17, 2016 12:13 PM EST
Get Alerts REGN Hot Sheet
Price: $364.43 +0.67%

Rating Summary:
    19 Buy, 18 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade REGN Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

BTIG affirms Regeneron Pharmaceuticals (Nasdaq: REGN) at Neutral after the company and Sanofi announced that the ongoing Praluent (alirocumab) ODYSSEY OUTCOMES trial will continue as planned, based on the recommendation of an independent Data Monitoring Committee (DMC) after it completed a second pre-specified interim analysis. The DMC will continue to monitor the ongoing safety and efficacy of Praluent as planned.

Analyst Dane Leone commented today: We were not expecting an early stop to the trial, but in tandem with limited differentiation of cardiovascular events within the Repatha trial, investors may remain cautious regarding the potential for success. Differentiation of cardiovascular outcomes remains a key potential driver for adoption of PCSK9 therapy relative to high dose statins, and will continue to be watched closely by the Street.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

BTIG

Add Your Comment